TABLE 1.
Evaluation of NG-Test CTX-M MULTI and MIC results of clinical K. oxytoca isolates and OXY-producing E. coli recombinant strains
| Strain | OXY variant | NG-Test CTX-M MULTIc | Minimal inhibitory concn (MIC) to:d |
||||||
|---|---|---|---|---|---|---|---|---|---|
| PIP | PTZ | CEF | CTX | CAZ | ATM | IMP | |||
| N85 | OXY-1-2 | + | >256 | >256 | >256 | 4 | 1 | >256 | 0.25 |
| N988 | OXY-1-3 | + | >256 | >256 | 256 | 0.5 | 0.25 | 16 | 0.25 |
| N1061 | OXY-1-3 | + | >256 | >256 | >256 | 1 | 1 | 32 | 0.25 |
| S175 | OXY-1-3 | + | >256 | >256 | 256 | 0.5 | 0.25 | 64 | 0.25 |
| N629 | OXY-1-4 | + | >256 | >256 | 128 | 0.25 | 0.25 | 32 | 0.25 |
| S148 | OXY-1-9 | + | >256 | >256 | 128 | 0.25 | 0.25 | 16 | 0.125 |
| N109 | OXY-2-1 | − | >256 | >256 | >256 | 1 | 0.25 | 64 | 0.125 |
| N828 | OXY-2-2 | − | >256 | >256 | >256 | 1 | 0.25 | 32 | 0.25 |
| N29 | OXY-2-3 | − | >256 | >256 | >256 | 4 | 1 | >256 | 0.25 |
| N496 | OXY-2-4 | − | >256 | >256 | >256 | >32 | 2 | >256 | 0.25 |
| R1057a | OXY-2-5 | − | >256 | >256 | >256 | >32 | >256 | 128 | 0.25 |
| N288 | OXY-2-6 | − | >256 | >256 | >256 | 1 | 0.5 | 64 | 0.25 |
| N683 | OXY-2-6 | − | >256 | >256 | >256 | 1 | 0.5 | 64 | 0.25 |
| N713 | OXY-2-6 | − | >256 | >256 | >256 | >32 | 1 | >256 | 0.5 |
| N794 | OXY-2-6 | − | >256 | >256 | >256 | 0.5 | 0.25 | 16 | 0.125 |
| R225b | OXY-2-6 | − | >256 | >256 | >256 | >32 | 64 | 64 | 0.5 |
| N94 | OXY-2-8 | − | >256 | >256 | >256 | 4 | 1 | >256 | 0.125 |
| N202 | OXY-2-8 | − | >256 | >256 | 256 | 0.5 | 0.25 | 16 | 0.125 |
| N630 | OXY-2-8 | − | >256 | >256 | >256 | 1 | 0.25 | 32 | 0.25 |
| S10 | OXY-2-8 | − | 128 | 16 | 64 | 0.125 | 0.5 | 1 | 0.125 |
| N761 | OXY-2-12 | − | >256 | >256 | >256 | 1 | 0.25 | 32 | 0.125 |
| R1056a | OXY-2-14 | − | >256 | >256 | >256 | >32 | 4 | >256 | 0.5 |
| OXY-1 T10 | OXY-1-2 | + | >256 | >256 | 256 | 2 | 0.5 | >256 | 0.25 |
| OXY-2 T10 | OXY-2-1 | − | >256 | 32 | >256 | 0.25 | 0.25 | 16 | 0.125 |
| OXY-1-mut T10 (KKS → NAA) | OXY-mut | − | >256 | >256 | >256 | 0.5 | 0.5 | 256 | 0.25 |
a
ESBL phenotype.
b
AmpC coproducer.
c
(+), positive result; (−), negative result.
d
PIP, piperacillin; PTZ, piperacillin-tazobactam; CEF, cephalotin; CTX, cefotaxime; CAZ, ceftazidime; ATM, aztreonam; IMP, imipenem.